Stay updated with breaking news from Poster Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® compared to epoetin alfa ...
New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® (luspatercept-aamt) compared to epoetin alfaPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #ASH--Bristol Myers Squibb (NYSE: BMY) announced updated results from the primary...
Study results support the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsiesGENOA, Italy--(BUSINESS WIRE)--#autism--IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, toda...
Completed merger with MedTech Acquisition Corporation and started public trading August 11th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior year and nine-month year to date net...
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected for presentation. The two abstracts show: the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and